推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 2016年8月，國(guó)家中醫(yī)藥管理局正式印發(fā)《中醫(yī)藥發(fā)展“十三五”規(guī)劃》，旨在推進(jìn)中醫(yī)藥振興發(fā)展，更好地為建設(shè)健康中國(guó)服務(wù)。
國(guó)家頻頻發(fā)文，重視中醫(yī)藥產(chǎn)業(yè)的發(fā)展。中醫(yī)藥事業(yè)正面臨著前所未有的大好機(jī)會(huì)。同時(shí)隨著社會(huì)的發(fā)展、健康觀念的轉(zhuǎn)變，在世界范圍內(nèi)，回歸自然、重視天然藥物已經(jīng)成為潮流。中國(guó)藥學(xué)家屠呦呦先生獲諾貝爾獎(jiǎng)再度引發(fā)世界對(duì)中醫(yī)藥的關(guān)注，以現(xiàn)代科學(xué)的方法進(jìn)行萃取和提純，遵循科學(xué)的標(biāo)準(zhǔn)確立其效果，證明了從傳統(tǒng)藥物獲得確定化學(xué)成分藥物的價(jià)值。中醫(yī)藥在國(guó)際市場(chǎng)的迅速普及，中醫(yī)藥標(biāo)準(zhǔn)化的國(guó)際呼聲日益高漲。有關(guān)國(guó)家紛紛開(kāi)展傳統(tǒng)醫(yī)藥標(biāo)準(zhǔn)的研究制定工作，以爭(zhēng)取國(guó)際標(biāo)準(zhǔn)制定主導(dǎo)權(quán)。
但中國(guó)中藥至今尚未真正進(jìn)入國(guó)際醫(yī)藥主流市場(chǎng)。中藥材種類多而國(guó)際標(biāo)準(zhǔn)缺乏、技術(shù)壁壘高、藥效和安全性的評(píng)價(jià)滯后，生產(chǎn)工藝、制劑技術(shù)的相對(duì)落后，使中國(guó)中藥難以在國(guó)際舞臺(tái)立足。資料顯示，目前為止，中國(guó)中藥海外份額僅占5%，而日本的漢方藥源于中藥，卻占據(jù)了世界中藥市場(chǎng)份額的70%。
